Supplementary Table 1. Inclusion and exclusion criteria

Inclusion criteria
1. Recent ischemic stroke that fulfills the following criteria 1) Relevant acute ischemic stroke confirmed by diffusion-weighted imaging 2) Randomization within 90 days after symptom onset 2. Statin therapy indicated according to the 2014 American Heart Association/American Stroke Association guidelines, satisfying at least one of the following three criteria: 1) Ischemic stroke due to arteriosclerosis and low-density lipoprotein cholesterol (LDL-C) ≥100 mg/dL 2) Ischemic stroke due to arteriosclerosis and LDL-C <100 mg/dL 3) Associated atherosclerotic cardiovascular disease, requiring statin therapy 3. No pre-stroke statin use within 28 days before the index ischemic stroke. 4. Baseline LDL-C level measured after the index ischemic stroke, satisfying at least one of the following criteria: 1) Baseline LDL-C level measured before initiating any statins after the index ischemic stroke 2) For patients who received non-study statins immediately after hospitalization before the study enrollment, the baseline LDL-C should be measured within 3 days of initiating non-study statins 5. Randomization and initiation of study medications within 7 days of the baseline LDL-C measurement 6. Age ≥19 7. Written informed consent
Exclusion criteria
1. Planned vascular intervention before the end of trial 2. Significant hepatic dysfunction (aspartate aminotransferase or alanine aminotransferase >120 IU/L) 3. Allergy or contraindication to rosuvastatin or ezetimibe 4. Alcohol or drug addiction 5. Pregnancy or breast-feeding 6. Severe anemia: hemoglobin level <10 g/dL for men and <9 g/dL for women 7. Bleeding diathesis: platelet count <100,000/μL or prothrombin time international normalized ratio (INR) >1.7 (Note: patients who were taking oral anticoagulation and INR >1.7 were eligible for enrollment) 8. Inability or unwillingness to comply with study-related procedures 9. Employees of the investigator or study center, with direct involvement in the current study 10. Women unwilling to continue contraception during the study period 11. Participation in other clinical trials within 3 months 12. Malignancy or other serious medical conditions with a life expectancy <6 months 13. Treatment with protease inhibitors or cyclosporine 14. Patients with severe renal impairment (creatinine clearance <30 mL/min) 15. Other reasons for ineligibility judged by investigators

Supplementary Table 2. Non-study statin use before randomization

	ROS10/EZT10 (n=273)	ROS20 (n=257)	*P*
Non-study statin initiation to randomization (day)	3.0±1.7	3.1±1.6	0.8958
Non-study statin use before randomization after hospitalization	193 (70.7)	188 (73.2)	0.5297
Atorvastatin	120 (62.2)	115 (61.2)	
Rosuvastatin	73 (37.8)	73 (38.8)	
Statin dose (mg/dL)*	49.7±22.4	53.0±23.5	0.1694

Data are presented as mean±standard deviation or n (%).
*Statin dose: converted to atorvastatin-equivalent dose.